{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T15:48:59Z","timestamp":1768319339172,"version":"3.49.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.jpba.2014.06.018","type":"journal-article","created":{"date-parts":[[2014,6,21]],"date-time":"2014-06-21T12:00:51Z","timestamp":1403352051000},"page":"407-416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Dual quantification of dapivirine and maraviroc in cervicovaginal secretions from ophthalmic tear strips and polyester-based swabs via liquid chromatographic\u2013tandem mass spectrometric (LC\u2013MS\/MS) analysis"],"prefix":"10.1016","volume":"98","author":[{"given":"Teresa L.","family":"Parsons","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua F.","family":"Emory","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren A.","family":"Seserko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wutyi S.","family":"Aung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Marzinke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2014.06.018_bib0005","series-title":"Global report: UNAIDS report on the global AIDS epidemic 2012","year":"2012"},{"key":"10.1016\/j.jpba.2014.06.018_bib0010","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(10)60676-9","article-title":"Antiretroviral therapy and management of HIV infections","volume":"376","author":"Volberding","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jpba.2014.06.018_bib0015","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1097\/01.aids.0000390705.73759.2c","article-title":"Postexposure prophylaxis, preexposure prophylaxis or universal test and treat: the strategic use of antiretroviral drugs to prevent HIV acquisition and transmission","volume":"24","author":"Weber","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.jpba.2014.06.018_bib0020","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1097\/QAD.0b013e3283543e83","article-title":"Antiviral agents and HIV prevention: controversies, conflicts and consensus","volume":"26","author":"Cohen","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.jpba.2014.06.018_bib0025","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11633630-000000000-00000","article-title":"HIV-1 antiretroviral resistance: scientific principles and clinical applications","volume":"72","author":"Tang","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.jpba.2014.06.018_bib0030","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1258\/ijsa.2011.011292","article-title":"Impact of antiretroviral dosing frequency and pill burden on adherence among newly diagnosed, antiretroviral-na\u00efve HIV patients","volume":"23","author":"Buscher","year":"2010","journal-title":"Int. J. STD AIDS"},{"key":"10.1016\/j.jpba.2014.06.018_bib0035","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s10461-012-0172-7","article-title":"A proposal for quality standards for measuring medication adherence in research","volume":"17","author":"Williams","year":"2013","journal-title":"AIDS Behav."},{"key":"10.1016\/j.jpba.2014.06.018_bib0040","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/QAI.0b013e31802bb35f","article-title":"Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers","volume":"44","author":"Jespers","year":"2007","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jpba.2014.06.018_bib0045","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1097\/QAD.0b013e32832c413d","article-title":"Safety, tolerability, and systemic absorption of dapivirine vaginal microbicidal gel in healthy, HIV-negative women","volume":"23","author":"Nel","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.jpba.2014.06.018_bib0050","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/QAI.0b013e3181acb536","article-title":"Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women","volume":"51","author":"Nel","year":"2009","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jpba.2014.06.018_bib0055","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1089\/aid.2009.0227","article-title":"Pharmacokinetic assessment of dapvirine vaginal microbicidal gel in healthy, HIV-negative women","volume":"26","author":"Nel","year":"2010","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.jpba.2014.06.018_bib0060","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1126\/science.1193748","article-title":"Effectiveness and safety of a tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women","volume":"329","author":"Karim","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.jpba.2014.06.018_bib0065","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ejps.2012.12.002","article-title":"A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action","volume":"48","author":"Fetherston","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2014.06.018_bib0070","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2147\/IJWH.S36282","article-title":"Vaginal rings for delivery of HIV microbicides","volume":"4","author":"Malcolm","year":"2012","journal-title":"Int. J. Women's Health"},{"key":"10.1016\/j.jpba.2014.06.018_bib0075","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/jac\/dks422","article-title":"Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques","volume":"68","author":"Malcolm","year":"2013","journal-title":"J Antimicrob. Chemother."},{"issue":"3","key":"10.1016\/j.jpba.2014.06.018_bib0080","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0092-8674(00)80110-5","article-title":"Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection","volume":"86","author":"Liu","year":"1996","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jpba.2014.06.018_bib0085","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/088922204322749567","article-title":"The CCR5 and CXCR4 coreceptors \u2013 central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection","volume":"20","author":"Moore","year":"2004","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.jpba.2014.06.018_bib0090","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1128\/AAC.01156-08","article-title":"Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor","volume":"53","author":"Fletcher","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"issue":"14","key":"10.1016\/j.jpba.2014.06.018_bib0095","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1056\/NEJMoa0803154","article-title":"Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection","volume":"359","author":"F\u00e4tkenheuer","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.jpba.2014.06.018_bib0100","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa0803152","article-title":"Maraviroc for previously treated patients with R5 HIV-1 infection","volume":"359","author":"Gulick","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2014.06.018_bib0105","doi-asserted-by":"crossref","first-page":"e15257","DOI":"10.1371\/journal.pone.0015257","article-title":"Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model","volume":"21","author":"Neff","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jpba.2014.06.018_bib0110","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1089\/aid.2008.0184","volume":"25","author":"Romano","year":"2009","journal-title":"AIDS Res. Hum. Reteroviruses"},{"key":"10.1016\/j.jpba.2014.06.018_bib0115","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/QAI.0b013e3181e3293a","article-title":"Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. hydroxyethyl cellulose-based universal placebo gel","volume":"55","author":"Nel","year":"2010","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jpba.2014.06.018_bib0120","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/jac\/dkt506","article-title":"Pharmacokinetics of a CCR5 inhibitor in rhesus macaques following vaginal, rectal and oral application","volume":"69","author":"Malcolm","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jpba.2014.06.018_bib0125","unstructured":"International Partnership for Microbicides, First efficacy trial of a microbicide ring to prevent HIV is underway, Available from: http:\/\/www.ipmglobal.org\/publications\/first-efficacy-trial-microbicide-ring-prevent-hiv-underway (accessed 15.04.14)."},{"key":"10.1016\/j.jpba.2014.06.018_bib0130","unstructured":"Microbicides Trials Network, ASPIRE \u2013 a study to prevent infection with a ring for extended use, Available from: http:\/\/www.mtnstopshiv.org\/news\/studies\/mtn020\/backgrounder (accessed 15.04.14)."},{"key":"10.1016\/j.jpba.2014.06.018_bib0135","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.4155\/tde.11.126","article-title":"The importance of the vaginal delivery route for antiretrovirals in HIV prevention","volume":"2","author":"Ferguson","year":"2011","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jpba.2014.06.018_bib0140","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s11904-011-0075-7","article-title":"Topical prophylaxis for HIV prevention in women: becoming a reality","volume":"8","author":"Verma","year":"2011","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"10.1016\/j.jpba.2014.06.018_bib0145","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.4155\/bio.13.256","article-title":"The development and validation of an UHPLC\u2013MS\/MS method for the rapid quantification of the antiretroviral agent dapivirine in human plasma","volume":"5","author":"Seserko","year":"2013","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2014.06.018_bib0150","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.cca.2014.02.008","article-title":"Development and bioanalytical validation of a liquid chromatographic\u2013tandem mass spectrometric (LC\u2013MS\/MS) method for the quantification of the CCR5 antagonist maraviroc in human plasma","volume":"431","author":"Emory","year":"2014","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jpba.2014.06.018_bib0155","series-title":"US Department of Health and Human Services UF, Center for Drug Evaluation and Research, Center for Veterinary Medicine: Guidance for Industry: Bioanalytical Method Validation","year":"2001"},{"key":"10.1016\/j.jpba.2014.06.018_bib0160","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1021\/ac971078+","article-title":"Matrix effect in quantitative LC\/MS\/MS analyses of biological fluids: a method for determination of finasteride in human plasma at pictogram per milliliter concentrations","volume":"70","author":"Matuszewski","year":"1998","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2014.06.018_bib0165","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3851\/IMP1919","article-title":"Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract","volume":"16","author":"Else","year":"2011","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.jpba.2014.06.018_bib0170","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1097\/QAD.0b013e328270385a","article-title":"Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis","volume":"21","author":"Dumond","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.jpba.2014.06.018_bib0175","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/QAI.0b013e3182575914","article-title":"The safety, persistence, and acceptability of an antiretroviral microbicide candidate UC781","volume":"60","author":"Bunge","year":"2012","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jpba.2014.06.018_bib0180","unstructured":"HIV Prevention Trials Network, HPTN-069, Phase II randomized, double-blind, study of safety and tolerability of maraviroc, maraviroc+emtricitabine, maraviroc+tenofovir, or tenofovir+emtricitabine for preexposure prophylaxis to prevent HIV transmission in at-risk men who have sex with men and in at-risk women: http:\/\/www.hptn.org\/research_studies\/hptn069.asp (accessed 15.04.14)."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708514003069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708514003069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T05:56:24Z","timestamp":1538546184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708514003069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":36,"alternative-id":["S0731708514003069"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2014.06.018","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual quantification of dapivirine and maraviroc in cervicovaginal secretions from ophthalmic tear strips and polyester-based swabs via liquid chromatographic\u2013tandem mass spectrometric (LC\u2013MS\/MS) analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2014.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}